Laboratory of Phospholipid Nanoparticles and Transport Systems 

Elena G. Tichonova Ph.D.



Olga M. Ipatova D.Sc.

Tatiana I. Torhovskaya D.Sc.

Tamara S. Zakharova Ph.D.

Yulia A. Tereshkina Ph.D.

Maxim A. Sangakov Ph.D.

Lubov V. Kostrukova

Evgenia I. Korotkevich

Natalia V. Kravchenkova

Aleksandr V. Danilov

Elena V. Kazlas

Valentina S. Baranova PH.D.


  • Development of technology for obtaining phospholipid nanoparticles of extremely small size as a drug transport system.

  • Embedding of medicinal substances of various pharmacotherapeutic groups in the phospholipid transport system.

  • Development of medicines based on the phospholipid transport system.

  • Study of the pharmacokinetics of medicinal compositions equipped with phospholipid nanoparticles.

  • Scaling up the technology for obtaining medicines equipped with transport nanosystems and developing appropriate regulatory and technical documentation.

  • Organization of preclinical and clinical trials of medicinal compositions.

  • Registration of new dosage forms.


  • The drug "Phosphogliv" (capsule and injectable forms), which is widely used in Russian healthcare

  • Technology for obtaining phospholipid nanoparticles with a size of less than 50 nm in the form of freeze-dried powder stable during storage and technological approaches for embedding biologically active compounds of various classes into the phospholipid nanosystem

  • An original drug conventionally named Phospholipovit based on phospholipid nanoparticles up to 30 nm in size. The drug has hypolipidemic properties and is in the form of powder for preparing a solution for oral administration. Its clinical study was conducted. The drug is recommended as a hypolipidemic agent in the complex therapy of atherosclerosis.

  • A new drug for intravenous administration for the treatment of oncological diseases, including breast cancer. The medicine is based on the anthracycline antibiotic doxorubicin in the composition of phospholipid nanoparticles. It has an intercalating mechanism of destructive action on the DNA and RNA of tumor cells. Its preclinical study was conducted